Gelonghui, May 30丨Tonghua Jinma (000766.SZ) held a performance briefing on May 29, 2024 to discuss “how much annual production can the production line support for the subsequent launch of new drugs?” The company replied that the company has a professional and dedicated new drug synthesis and formulation workshop, the production system is built according to GMP requirements, and the design capacity can meet the medication needs of patients with Alzheimer's disease in China.
通化金马(000766.SZ)：建有专业、专门的新药合成、制剂车间，设计产能可以满足国内阿尔茨海默病患者的用药需求
Tonghua Jinma (000766.SZ): We have built a professional and dedicated new drug synthesis and formulation workshop. The design capacity can meet the medication needs of patients with Alzheimer's disease in China
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.